Cancer

Article	Citations
Cutaneous β‐HPV may predict cutaneous squamous cell carcinoma	449
The role of relative advantage for development of sequencing‐based diagnostics for pediatric cancer in low‐ and middle‐income countries	301
	214
Active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer	192
Issue Information	191
The economics of advanced and unresectable hepatocellular carcinoma	138
New standard of care for multiple myeloma?	132
Updated American Cancer Society lung cancer screening guidelines	106
Best of both worlds? Linking comprehensive and noncomprehensive cancer centers	74
Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies	73
MRI is more accurate than a PSMA PET/CT scan for prostate cancer diagnosis	62
Smoking cessation services and shared decision‐making practices among lung cancer screening facilities: A cross‐sectional study	62
Serum of interleukin‐6 and procalcitonin as early diagnostic markers for the identification of poor hematopoietic reconstitution following allogeneic hematopoietic stem cell transplantation	60
Potential of circulating tumor DNA to refine immunotherapy	60
Reply to “Enhancing the role of social work in managing cancer risks among LGBTQ+ populations” and “The urgency of systematically acquiring sexual orientation and gender identity data to ensure equity	59
Erratum to “Landscape of DNA damage response gene alterations in breast cancer: A comprehensive investigation”	59
Aspirin but not statins is inversely related to gastric cancer with a duration–risk effect: Results from the Stomach Cancer Pooling Project Consortium	57
Multicenter study of pediatric Epstein‐Barr virus–negative monomorphic post solid organ transplant lymphoproliferative disorders	57
Patterns of failure in pediatric medulloblastoma and implications for hippocampal sparing	57
Family characteristics and childcare patterns associated with early social functioning in cancer‐bereaved parents	56
	55
Accelerated approval of multiple myeloma therapies	54
Issue Information	53
Erratum to “Incorporation of alemtuzumab into frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study”	53
“Cancer Statistics, 2025” provides data on cancer occurrence and outcomes	52

Top advances of the year: Neoadjuvant immunotherapy in melanoma	52
Reply to “Empathic communication: The premise of inclusive care for historically excluded populations”	51
Erratum to “Chimeric antigen receptor–based immunotherapy in breast cancer: Recent progress in China”	51
	50
What enhanced recovery means for patients with cancer undergoing surgery	50
	50
Detection of recurrent colorectal cancer with high specificity using a reporting threshold for circulating tumor DNA methylated in BCAT1 and IKZF1	50
Issue Information	49
Issue Information	48
Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemia	48
Erratum to “Unhealthy lifestyle behaviors, overweight, and obesity among childhood cancer survivors in the Netherlands: A DCCSS LATER study”	47
	47
New test for detecting cervical adenocarcinoma	45
Implantable cardioverter defibrillators in people dying with cancer: A SEER‐Medicare analysis of ICD prevalence and association with aggressive end‐of‐life care	45
Can we avoid thoracic radiotherapy in young females with Hodgkin lymphoma?	43
The Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer (CISTO) study: Lessons learned about management and patient enrollment in a large, pragmatic, patient‐centere	43
Understanding risk factors for cancer: What's new and how can it help reduce the cancer burden?	43
Stopping immunotherapy after 2 years is practical in patients with advanced non–small cell lung cancer	43
Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation	40
Sharp rise in esophageal cancer and Barrett esophagus seen in middle‐aged people	40
Long‐term follow‐up of a phase 2 study of all‐trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia	38
Dietary supplement use among adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort Study	38
A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first‐line treatment for patients with melanoma in‐transit metastases	38
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3‐tyrosine kinase domain mutations: Prognostic implications of NPM1 co‐mutation	38
Radiation necrosis in renal cell carcinoma brain metastases treated with checkpoint inhibitors and radiosurgery: An international multicenter study	37
The critical need to implement and utilize patient‐reported measures of function in cancer care delivery	37
Epistemic equity in oncology: Opportunities to leverage patient‐centric implementation in clinical trial design	37
Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK‐positive advanced non–small cell lung cancer	37
Effect of smoking reduction, cessation, and resumption on cancer risk: A nationwide cohort study	37
Occurrence of breast‐cancer–related lymphedema after reverse lymphatic mapping and selective axillary dissection versus standard surgical treatment of axilla: A two‐arm randomized clinical trial	37
Unveiling the impact of chemotherapy in patients with breast cancer: A longitudinal study on peripheral inflammation, multimodal magnetic resonance imaging, and cognition	36
Redefining the “crown”: Approaching chemotherapy‐induced alopecia among Black patients with breast cancer	36
A guide to large data sets for population‐based cancer research: Strengths, limitations, and pitfalls	36
Ovarian juvenile granulosa cell tumor: A report from the International Ovarian and Testicular Stromal Tumor and International Pleuropulmonary Blastoma/DICER1 Registries	36
Financial toxicity impact on younger versus older adults with cancer in the setting of care delivery	36
Updates on research and management of gastrointestinal stromal tumors in China	36
Effect of an mHealth intervention on physical activity outcomes among young adult cancer survivors: The IMPACT randomized controlled trial	36
Improved survival and decreased cancer deaths in young adults with cancer after passage of the Affordable Care Act Dependent Coverage Expansion	36
Implications of omitting sentinel lymph node biopsy on adjuvant decision making for patients with small breast cancers	36
Development and validation of a machine‐learning–based pathomics nomogram for predicting recurrence of localized primary gastrointestinal stromal tumors after complete surgical resection: A retrospect	36
Association between visceral adiposity index and cancer risk in the UK Biobank cohort	35
Top advances of the year: Cervical cancer	33
Midlife baseline prostate‐specific antigen, velocity, and doubling time association with lethal prostate cancer and mortality	33
Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53	33
Disparities in prostate cancer screening, diagnoses, management, and outcomes between Indigenous and non‐Indigenous men in a universal health care system	33
Impact of African ancestry on the relationship between body mass index and survival in an early‐stage breast cancer trial (ECOG‐ACRIN E5103)	33
Correction to “Chronic myelomonocytic leukemia in the young (aged 50 years and younger): Divergent clinical and molecular characteristics from the elderly”	32
Characteristics of clinical trials of new oncology drugs approved in China	32
International perspectives on the development, application, and evaluation of a multicancer early detection strategy	32
Risk scores predicting disease progression in early‐stage chronic lymphocytic leukemia: Comparative analysis and usefulness of IGHV subset #2 to improve their accuracy	31

What are the most effective exercise, physical activity and dietary interventions to improve body composition in women diagnosed with or at high‐risk of breast cancer? A systematic review and network	31
Breast cancer survival in India across 11 geographic areas under the National Cancer Registry Programme	31
Lung cancer screening use and implications of varying eligibility criteria by race and ethnicity: 2019 Behavioral Risk Factor Surveillance System data	31
Recent histone deacetylase inhibitors in cancer therapy	31
What’s the reality for CDK4/6 inhibitors: Clinical trials or real‐world evidence?	31
Significance of HIV status in cervical cancer patients receiving curative chemoradiation therapy, definitive radiation alone, or palliative radiation in Botswana	30
The American Cancer Society National Lung Cancer Roundtable strategic plan: Introduction	30
Cervical cancer elimination in Indian context: Moving from barriers to facilitators	30
Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG‐ACRIN analysis	30
Olaparib in treatment‐refractory isocitrate dehydrogenase 1 (IDH1)– and IDH2‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 tri	30
Impact of baseline tumor burden on overall survival in patients with radioiodine‐refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial	30
Comparison of long‐term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia‐positive acute lymphoblastic leukemia: A multicente	30
Racial inequities in the quality of surgical care among Medicare beneficiaries with localized prostate cancer	30
Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma	29
Long‐term outcomes of ripretinib versus sunitinib in Chinese patients with advanced gastrointestinal stromal tumor: An updated analysis of a phase 2 randomized clinical trial	29
	28
Correlation analysis of invasive disease‐free survival and overall survival in a real‐world population of patients with HR+/HER2– early breast cancer	28
A call to action to advance patient‐focused and decentralized clinical trials	28
Patterns of lung cancer incidence in adults diagnosed under age 50 in the United States, 2000–2021	28
Associations between geography, decision‐making style, and interest in cancer clinical trial participation	27
Prospective associations between sleep quality and sexual satisfaction in distressed breast cancer survivors: Secondary analysis from the Apps Reaching Cancer Survivors randomized trial	27
Impact of acupuncture and integrative therapies on chemotherapy‐induced peripheral neuropathy: A multicentered, randomized controlled trial	27
Treatment of children with favorable histology Wilms tumor with extrapulmonary metastases: A report from the COG studies AREN0533 and AREN03B2 and NWTSG study NWTS‐5	27
A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF‐mutated cancers	27
Seroconversion and outcomes after initial and booster COVID‐19 vaccination in adults with hematologic malignancies	27
Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial	27
Avelumab treatment for patients with metastatic Merkel cell carcinoma can be safely stopped after 1 year and a PET/CT–confirmed complete response	27
	26
Association of mental health treatment receipt with cancer screening among US adults with a history of anxiety or depression	26
Estimating oncologist variability in prescribing systemic cancer therapies to patients in the last 30 days of life	26
Helping patients with cancer to understand secondary findings on genetic tests	26
Safety, efficacy, and pharmacokinetics of SH‐1028 in EGFR T790M‐positive advanced non–small cell lung cancer patients: A dose‐escalation phase 1 study	26
Issue Information	25
Physical fitness and clinically assessed disease burden in long‐term childhood cancer survivors—The SURfit study	25
Beyond the PSA: The hidden costs of screening in prostate cancer	25
From childhood cancer to metabolic syndrome	25
Continuity and coordination of care for childhood cancer survivors with multiple chronic conditions: Results from the Childhood Cancer Survivor Study	25
	25
Standard of care for children with newly diagnosed B‐cell ALL	25
Real‐world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia	24
Issue Information	24
	24
Associations between experiences of discrimination and quality of life in Black breast cancer survivors	24
Anlotinib in combination with docetaxel for advanced nonsmall cell lung cancer after failure of platinum‐based treatment: A phase 1/2 trial	24
Anti‐Müllerian hormone for assessing ovarian toxicity of cancer treatment in young women: It’s complicated	24
Targeting ROS1 rearrangements in non–small cell lung cancer: Current insights and future directions	24
	24
Making a case for del(1p) as a high‐risk abnormality in multiple myeloma	24
Keep moving to prevent cancer	23
Is it time for bone marrow sparing radiation therapy to be standard of care in cervical cancer?	23
Select cases might get a benefit from chemotherapy for Stage I pT1aN0M0 HER2+ breast cancer	23
Prevalence and determinants of metabolic syndrome in 2338 childhood cancer survivors: A Dutch Childhood Cancer Survivor LATER 2 study	23
Immune check point inhibitors in advanced cutaneous squamous cell carcinomas: “Repeat and replicate”	23
Young adult males have worse survival than females that is largely independent of treatment received for many types of central nervous system tumors: A National Cancer Database analysis	23
Outcomes of radiofrequency ablation for hepatocellular carcinoma with concurrent steatotic liver disease	23
Issue Information	23
The protective role of postoperative radiation therapy in low and intermediate grade major salivary gland malignancies: A study of the Canadian Head and Neck Collaborative Research Initiative	23
Association between treatment‐emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study	23
Issue Information	23
Lost in the shadow of giants: The neglected treatment modalities in oncologic trials	23
Utilization and perceptions of chaplaincy among hospitalized adults of Dharmic religions with cancer	23
The use of national datasets to evaluate outcomes for invasive lobular carcinoma	23
Diabetes mellitus and neurocognition: A report from the Childhood Cancer Survivor Study	22
The Prostate Cancer Active Lifestyle Study (PALS): A randomized controlled trial of diet and exercise in overweight and obese men on active surveillance	22
Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma	22
Landscape and clinical impact of NOTCH mutations in newly diagnosed acute myeloid leukemia	22
Impact of the COVID‐19 pandemic on pediatric oncology providers globally: A mixed‐methods study	22
Sex disparities in the incidence of 21 cancer types: Quantification of the contribution of risk factors	22
Clinical implications of tumor‐based next‐generation sequencing in high‐grade epithelial ovarian cancer	22
Effect of preoperative programmed death‐1 or programmed death ligand‐1 immune check point inhibition on complications after surgery for primary head and neck cancer	22
Acute hospitalizations after proton therapy versus intensity‐modulated radiotherapy for locally advanced non–small cell lung cancer in the durvalumab era	22
A randomized prospective trial of an ostomy telehealth intervention for cancer survivors	22
The relationship of mental health symptoms to chemotherapy toxicity risk in older adults with cancer: Results from the geriatric assessment–driven intervention study	21
Nomogram predicts survival and surgical benefits for patients with breast cancer with initial bone metastasis: A population‐based study	21
Cancer treatment in the time of COVID‐19 pandemics: A new concern	21
Lung cancer screening associated with earlier diagnosis and improved survival	21
Oncologists’ role in end‐of‐life chemotherapy and patient‐centered care	21
The American Cancer Society National Lung Cancer Roundtable strategic plan: Tobacco treatment in the context of lung cancer screening	21
Association between exposures to radon and γ‐ray radiation and histologic type of lung cancer in Eldorado uranium mining and milling workers from Canada	21
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry	21

Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III–IVa cervical cancer: is the ENGOT‐cx11/GOG‐3047/KEYNOTE‐A18 trial practice changing?	21
CD123 expression linked to high‐risk disease in children with acute myeloid leukemia	21
Triple‐negative breast cancer survival prediction using artificial intelligence through integrated analysis of tertiary lymphoid structures and tumor budding	21
Erratum to “Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children’s Oncology Group”	21
First person profile: Fadlo R. Khuri, MD	21
Primary osteosarcoma of the ribs: A report from the Cooperative Osteosarcoma Study Group	21
First person profile: Robert C. Bast Jr MD	21
Palliative care training can help patients with advanced cancer at the end of life	20
Gaps in care highlight the need to expand access to clinical cancer trials	20
Phase 1 trial of intraperitoneal paclitaxel in patients with gastric adenocarcinoma and carcinomatosis or positive cytology	20
Assessment of the compliance, influencing factors, and yielding results of liver cancer screening in a high‐risk population: A cross‐sectional study	20
An editorial on a comparison of care quality metrics between Black and White men with advanced prostate cancer in the IRONMAN registry	20
Targeted genotyping for recurring variants in cancer susceptibility genes in non‐Ashkenazi Jewish patients with breast cancer diagnosed ≥50 years	20
Breast health equity along the cancer care continuum: A collaborative grant initiative	20
Reply to “Another look at floor and ceiling effects in the EORTC QLQ‐C30 Physical Functioning subscale and possible solutions”	20
Issue Information	20
AACR 2024 presents advancements in pancreatic and gastric cancers	20
Hepatocellular carcinoma, vascular endothelial growth factor receptors‐targeting agents, and hypertension: A much more complicated relationship than expected	20
Issue Information	19
Is repeat breast conservation possible for small ipsilateral breast cancer recurrence?	19
Health‐related quality of life outcomes after neoadjuvant chemoradiotherapy for rectal cancer in NRG Oncology/NSABP R‐04	19
Defining disease modification in myelofibrosis in the era of targeted therapy	19
Staging lymph nodes and blood at diagnosis in mycosis fungoides identifies patients at increased risk of progression to advanced stage: A retrospective cohort study	19
Stage I epithelial or stromal type Wilms tumors are low risk tumors: An analysis of patients treated on the SIOP‐WT‐2001 protocol in the UK‐CCLG and GPOH studies (2001–2020)	19
Glioma mutational signatures associated with haloalkane exposure are enriched in firefighters	19
	19
Cumulative incidence and risk factors of brain metastases in metastatic non–small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from IMpower130, IM	19
Circulating tumor DNA‐based molecular residual disease detection for treatment monitoring in advanced melanoma patients	19
Top advances of the year: Targeted therapy for lung cancer	19
EGFR exon 20–targeting sunvozertinib granted accelerated approval for advanced NSCLC	19
Safety and promising efficacy with enhanced CAR T‐cell therapy for lymphoma	19
Implementation and evaluation of a remote geriatric assessment and intervention program in Brazil	19
CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study	19
Geographic diffusion of digital mammography in the United States	19
Factors associated with prostate cancer screening among Hispanic men: Results from the Hispanic Community Health Study/Study of Latinos	19
Cannabis use among adults undergoing cancer treatment	18
Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study	18
Endoscopic balloon cryoablation plus transurethral resection for bladder cancer: A phase 2, multicenter, randomized, controlled trial	18
Cyclin‐dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple‐negative breast cancer by affecting the immune microenvironment	18
Multidimensional structural racism and estimated cancer risk from traffic‐related air pollution	18
A prospective study on diagnostic accuracy of technology‐enabled early detection of oral cancer and epidemiology of tobacco and other substances use in rural India	18
A phase 2 multicenter study of docetaxel‐PM and trastuzumab‐pkrb combination therapy in recurrent or metastatic salivary gland carcinomas	18
Reasons for refusal of the human papillomavirus vaccine among young cancer survivors	18
Comparison of survival outcomes for patients with Stage III vs de novo Stage IV breast cancer	18
Association between the amount of artificial hydration and quality of dying among terminally ill patients with cancer: The East Asian Collaborative Cross‐Cultural Study to Elucidate the Dying Process	18
Effects of exercise therapy on chemotherapy delivery and response in primary breast cancer: A secondary analysis of a randomized trial	18
Top advances of the year in colorectal cancer	18
Determinants of geographic variation in the incidence of adult nonmalignant meningioma in the United States, 2010–2019	18
A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non–small cell lung cancer with EGFR mutation	17
Burden of female‐specific cancers in China from 1990 to 2021: A systematic analysis for the Global Burden of Disease Study 2021	17
Cytokine release syndrome in solid tumors	17
Cancer‐related inflammation and depressive symptoms: Systematic review and meta‐analysis	17
Pre‐ and on‐treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non–small cell lung cancer	17
A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies	17
Reply to “How should decision aids be developed, and which patient outcomes should be assessed?”	17
Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago‐gastric Diseases (PROCEED): A single‐arm phase 2 trial	17
Parents’ and adolescents’ perspectives and understanding of information about childhood cancer precision medicine	17
Social relationships and their impact on health‐related quality of life in a long‐term breast cancer survivor cohort	17
Issue Information	17
The cost burden of metastatic prostate cancer in the US populations covered by employer‐sponsored health insurance	17
Issue Information	17
Associations of serum trimethylamine N‐oxide and its precursors with colorectal cancer risk in the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial Cohort	17
Comparing clinical and nonclinical cancer patient navigators: A national study in the United States	17
Top advances of the year: Reappraisal of systemic versus local therapy for hepatocellular carcinoma	17
American Radium Society Appropriate Use Criteria for the use of liver‐directed therapies for nonsurgical management of liver metastases: Systematic review and guidelines	17
Chronic conditions, cancer disparities, and the unique needs of Black women with ovarian cancer	17
	16
	16
Impact of resistance training on inflammatory biomarkers and associations with treatment outcomes in colon cancer	16
Cancer survivors have an increased risk of cardiovascular disease	16
Genomics likely are not the main driver in advanced prostate cancer overall survival rate disparities	16
First person profile: Julie Brahmer, MD	16
	16
Incidence rates of soft tissue sarcoma among U.S. military servicemen: Comparison with the rates in the general U.S. population	16
Generalizing approaches to surveillance for complex social outcomes in broad‐range patient populations—The cost in terms of lost information and subgroup utility	16
Caring for caregivers in early‐phase clinical oncology trials	16
Issue Information	16
	16
Cancer registries: A look back and forward	16
Potential new standard of care for the first‐line treatment of metastatic colorectal cancer	16
Issue Information	16
When destiny doesn’t pan out: Implications for the treatment of sarcomas after the agnostic approval of trastuzumab deruxtecan	16
Systemic therapies at the end of life vary by patient and practice	16
Provider motivations and barriers to cancer clinical trial screening, referral, and operations: Findings from a survey	16
	16
Associations between birth defects with neural crest cell origins and pediatric embryonal tumors	15
New persistent opioid use among adolescents and young adults with sarcoma	15
Top advances of the year: Cervical cancer	15
The American Cancer Society National Lung Cancer Roundtable strategic plan: Advancing comprehensive biomarker testing in non–small cell lung cancer	15
Phase 1b study of pan‐AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN‐mutated advanced solid tumors	15
Racial disparities in the screening mammography continuum within a heterogeneous health care system	15
Disparities in cancer genetics care by race/ethnicity among pan‐cancer patients with pathogenic germline variants	15
Cancer incidence in the US military: An updated analysis	15
Cumulative exposure to impaired fasting glucose and gastrointestinal cancer risk: A nationwide cohort study	15
Characterization of HER2‐low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study	15